Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Change in Cash (2016 - 2025)

Mimedx's Change in Cash history spans 15 years, with the latest figure at $24.0 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 53.94% year-over-year to $24.0 million; the TTM value through Dec 2025 reached $61.7 million, up 175.27%, while the annual FY2025 figure was $61.7 million, 175.27% up from the prior year.
  • Change in Cash for Q4 2025 was $24.0 million at Mimedx, up from $23.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $24.0 million in Q4 2025 and bottomed at -$33.5 million in Q1 2024.
  • The 5-year median for Change in Cash is $1.4 million (2023), against an average of $3.5 million.
  • The largest annual shift saw Change in Cash crashed 1316.09% in 2022 before it soared 1767.82% in 2024.
  • A 5-year view of Change in Cash shows it stood at -$3.5 million in 2021, then crashed by 106.21% to -$7.3 million in 2022, then soared by 111.5% to $836000.0 in 2023, then skyrocketed by 1767.82% to $15.6 million in 2024, then skyrocketed by 53.94% to $24.0 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Change in Cash are $24.0 million (Q4 2025), $23.2 million (Q3 2025), and $12.4 million (Q2 2025).